림프종 · FRα

51개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved51 programs
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART22 cells (CART22 cells)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Discontinued
AntibodyLimited DatastaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 4Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Active
CGTLimited DatastaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleNektar TherapeuticsPhase 1

Polymer-conjugated IL-15 Receptor Agonist NKTR-255 (Polymer-conjugated IL-15 Receptor Agonist NKTR-255)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
AntibodyLimited DatastalePETHEMA FoundationPhase 2

ibritumomab tiuxetan (ibritumomab tiuxetan)

Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 2Status Discontinued
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryPeripheralTC+2
Trials 1Status Recruiting
CGTLimited DatastaleMayo ClinicPhase 1

Autologous BAFFR-targeting CAR T Cells (Autologous BAFFR-targeting CAR T Cells)

B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous CCR4 CAR T cells (Autologous CCR4 CAR T cells)

Relapsed and/or Refractory Mature T Cell Malignancy; Peripheral T-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD5/CD7 dual-target CAR-T module (Autologous CD5/CD7 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#antibody-drug-conjugate#RelapsedorRefractoryHodgkinLymph+1
Trials 1Status Active
CGTLimited DatastaleKitePhase 2

other names: brexu-cel , Tecartus (Brexucabtagene autoleucel, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus))

Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

CAR T cells chimeric antigenreceptor cells (CAR T cells chimeric antigenreceptor cells)

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Relapsed/Refractory B-cell ALL · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstituto de Investigación Biom…Phase 2

CAR-T cells therapy (CAR-T cells therapy)

Refractory B-Cell Lymphoma; B-cell Lymphoma Recurrent · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen University General Hos…Phase 2

CAR/TRuC-T (CAR/TRuC-T)

Relapsed/Refractory B-cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 2

CAR2219-T cells (CAR2219-T cells)

Relapsed or Refractory B Cell Leukemia and Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

CD70 CAR-NK (CD70 CAR-NK)

Relapsed/Refractory T-cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

CXCR4 CCR9 CAR-T (CXCR4 CCR9 CAR-T)

Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleCaribou Biosciences, Inc.Preclinical

Caribou-sponsored investigational therapy (Caribou-sponsored investigational therapy)

Lymphoma, Non-Hodgkin; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleJennifer Crombie, MDPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) Therapy Infusion)

Primary Mediastinal Large B-cell Lymphoma (PMBCL); Primary Mediastinal Large B Cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

2 / 3 pages

← PreviousNext →